Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
FAST NEWS: Genscript’s controlling shareholder sells shares to Hillhouse Capital
The latest: Genscript Biotech Corp. (1548.HK) announced Wednesday its controlling shareholder Genscript Corp. will sell 85.78 million shares, or about 0.4% of its shares, to GNS II Holdings Ltd, a subsidiary…
FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter…
FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses
The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
FAST NEWS: Legend Biotech shares jump on rising cancer drug sales
The latest: Cell therapy company Legend Biotech Corp. (LEGN.US) recorded net sales of $117 million in the second quarter for its Carvykti cancer drug, up 65% from the previous quarter, according to…
FAST NEWS: Hillhouse invests $22 million in Legend Biotech
The latest: Genscript Biotech Corp. (1548.HK) announced on Sunday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) has sold 692,782 shares through a private placement to LGN Holdings Ltd.,…
FAST NEWS: Legend Biotech to raise $300 million from share sale
The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by…
